- Home
- FTF vs PHAT Comparison
FTF vs PHAT Comparison
Compare FTF & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTF
- PHAT
- Stock Information
- Founded
- FTF 2003
- PHAT 2018
- Country
- FTF United States
- PHAT United States
- Employees
- FTF N/A
- PHAT N/A
- Industry
- FTF Finance/Investors Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- FTF Finance
- PHAT Health Care
- Exchange
- FTF Nasdaq
- PHAT Nasdaq
- Market Cap
- FTF 256.8M
- PHAT 727.5M
- IPO Year
- FTF N/A
- PHAT 2019
- Fundamental
- Price
- FTF $6.42
- PHAT $9.16
- Analyst Decision
- FTF
- PHAT Strong Buy
- Analyst Count
- FTF 0
- PHAT 5
- Target Price
- FTF N/A
- PHAT $16.40
- AVG Volume (30 Days)
- FTF 153.9K
- PHAT 4.9M
- Earning Date
- FTF 01-01-0001
- PHAT 08-07-2025
- Dividend Yield
- FTF 11.45%
- PHAT N/A
- EPS Growth
- FTF N/A
- PHAT N/A
- EPS
- FTF N/A
- PHAT N/A
- Revenue
- FTF N/A
- PHAT $81,859,000.00
- Revenue This Year
- FTF N/A
- PHAT $195.45
- Revenue Next Year
- FTF N/A
- PHAT $106.76
- P/E Ratio
- FTF N/A
- PHAT N/A
- Revenue Growth
- FTF N/A
- PHAT 3055.70
- 52 Week Low
- FTF $5.76
- PHAT $2.21
- 52 Week High
- FTF $6.56
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- FTF 56.91
- PHAT 64.16
- Support Level
- FTF $6.33
- PHAT $9.25
- Resistance Level
- FTF $6.45
- PHAT $10.13
- Average True Range (ATR)
- FTF 0.04
- PHAT 0.91
- MACD
- FTF 0.00
- PHAT -0.19
- Stochastic Oscillator
- FTF 85.71
- PHAT 32.96
About FTF Franklin Limited Duration Income Trust of Beneficial Interest
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.